

09/336,266

=> d his

(FILE 'HOME' ENTERED AT 15:29:02 ON 31 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:29:08 ON 31 AUG 2000

L1 STRUCTURE UPLOADED

L2 1 S L1 SSS SAM

L3 95 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:30:13 ON 31 AUG 2000

L4 2 S L3

FILE 'CAOLD' ENTERED AT 15:31:34 ON 31 AUG 2000

=> s l3

L5 0 L3

09/336,266

=>


Uploading 09336266.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1

G2 N, CH

G3 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:35:53 FILE 'MARPAT'

SAMPLE SCREEN SEARCH COMPLETED - 1148 TO ITERATE

87.1% PROCESSED 1000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.08

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 21089 TO 24831


PROJECTED ANSWERS: 1 TO 86

L2 1 SEA SSS SAM L1


=> d scan l2

L2 1 ANSWERS MARPAT COPYRIGHT 2000 ACS  
 IC ICM C07D213-84  
 ICS A01N043-40; A01N047-36; A01N047-18  
 CC 27-16 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 5  
 TI Preparation of fungicidal anilinocyanopyridines  
 ST anilinocyanopyridine prepn agrochem fungicide; cyanopyridine anilino  
 prepn  
 fungicide; pyridine anilinocyano prepn fungicide  
 IT Fungicides and Fungistats  
 (agrochem., anilinocyanopyridines as)  
 IT 132132-94-6P 132132-95-7P 132132-96-8P 132132-97-9P 132132-98-0P  
 132132-99-1P 132133-00-7P 132133-01-8P 132133-02-9P 132133-03-0P  
 132133-04-1P 132133-05-2P 132133-06-3P 132133-07-4P 132133-08-5P  
 132133-09-6P 132133-10-9P 132133-11-0P 132133-12-1P 132133-13-2P  
 132133-14-3P 132133-15-4P 132133-16-5P 132133-17-6P 132133-18-7P  
 132133-19-8P 132133-20-1P 132133-21-2P 133946-48-2P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of, as fungicide)  
 IT 29091-09-6 30464-06-3  
 RL: RCT (Reactant)  
 (reaction of, in prepn. of fungicides)  
 IT 98-09-9, Benzenesulfonyl chloride  
 RL: RCT (Reactant)  
 (sulfonylation by, of anilinocyanopyridine deriv., in prepn. of  
 fungicides)


## MSTR 1



G1 = OPh (SO)  
 G4 = 22



G7 = 34



G9 = NH2

09/336,266

DER: and salts with plant acceptable cations  
MPL: claim 1

ALL ANSWERS HAVE BEEN SCANNED

09/336,266

=> s l1 sss ful

FULL SEARCH INITIATED 13:36:24 FILE 'MARPAT'  
FULL SCREEN SEARCH COMPLETED - 23310 TO ITERATE

20.8% PROCESSED	4852 ITERATIONS	( 1 INCOMPLETE)	4 ANSWERS
43.1% PROCESSED	10049 ITERATIONS	( 2 INCOMPLETE)	10 ANSWERS
62.6% PROCESSED	14581 ITERATIONS	( 2 INCOMPLETE)	15 ANSWERS
84.5% PROCESSED	19694 ITERATIONS	( 2 INCOMPLETE)	21 ANSWERS
94.7% PROCESSED	22085 ITERATIONS	( 2 INCOMPLETE)	23 ANSWERS
98.8% PROCESSED	23030 ITERATIONS	( 2 INCOMPLETE)	23 ANSWERS
100.0% PROCESSED	23310 ITERATIONS	( 2 INCOMPLETE)	23 ANSWERS

SEARCH TIME: 00.02.00

L3 23 SEA SSS FUL L1

=> d l3 1-23 bib,abs

L3 ANSWER 1 OF 23 MARPAT COPYRIGHT 2000 ACS

AN 132:308342 MARPAT

TI Preparation of pyridyl-1,2,4-triazoles as acaricides and insecticides

IN Tisdell, Francis E.; Johnson, Peter L.; Pechacek, James T.; Bis, Scott J.;

Hedge, Vidyadhar B.; Schoonover, Joe R., Jr.; Ripa, Perry V.; Dintenfass, Leonard P.; Gifford, James M.; Thibault, Thomas D.; Ash, Mary L.;

Devries,

Donald H.; Martin, Timothy P.

PA Dow Agrosciences Llc, USA

SO PCT Int. Appl., 68 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024735	A1	20000504	WO 1999-US24751	19991022
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-105356		19981023		
GI					



AB Title compds. [I; 1 of X,Y = H, alkyl, Ph, etc. and the other = (un)substituted Ph, -pyridyl, -thienyl, etc.; Z = (un)substituted pyridyl]

were prepd. Thus, 3,5-dichloro-4-pyridinethioamide was S-methylated and the product N-acylated by 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>COCl to give ZC(SMe):NCOC<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>-2,4 (Z = 3,5-dichloro-4-pyridyl) which was cyclocondensed with MeNHNH<sub>2</sub> to give

I (X = Me, Y = C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>-2,4, Z = 3,5-dichloro-4-pyridyl). Data for biol. activity of I were given.

RE.CNT 11



RE

- (1) Baldwin, J; US 3984558 A 1976 CAPLUS
- (2) Baldwin, J; US 4011218 A 1977 CAPLUS
- (5) Goedecke Ag; DE 2258036 A 1974 CAPLUS
- (8) Lepetit Spa; DE 2358011 A 1974 CAPLUS
- (9) Novello, F; US 3963731 A 1976 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 132:222531 MARPAT  
 TI Preparation of thiazole derivatives as p38 inhibitors  
 IN Salituro, Francesco; Bemis, Guy; Cochran, John  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000017175	A1	20000330	WO 1999-US21337	19990916
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9962514	A1	20000410	AU 1999-62514	19990916
PRAI	US 1998-100972		19980918		
	WO 1999-US21337		19990916		
GI					



AB The present invention provides inhibitors of p38 having general formulas  
 I  
 and II [ X = O, S, NR or C(R)2; Y = CR or N; Z = CH or N; M = CO, CHOH,  
 or  
 CH2; n = 0 or 1; Q1 = 5-6 membered arom. carbocyclic or heterocyclic ring  
 system, or an 8-10 membered bicyclic ring system comprising arom.  
 carbocyclic rings, arom. heterocyclic rings or a combination of an arom.  
 carbocyclic ring and an arom. heterocyclic ring, and Q2 = H, CO7R',

CON(R')<sub>2</sub>, or a (C1-c4) branched or straight-chain alkyl optionally contg. 1-3 substituents independently selected from A, T-C(O)R', OPO<sub>3</sub>H<sub>2</sub>, NR'<sub>2</sub>, N(R'), OR', CO<sub>2</sub>R', CON(R')<sub>2</sub>, or SO<sub>2</sub>N(R<sub>2</sub>)<sub>2</sub>; or a 5-6 membered arom. carbocyclic or heterocyclic ring system, or an 8-10 membered bicyclic ring system comprising arom. carbocyclic rings, arom. heterocyclic rings or a combination of an arom. carbocyclic ring and an arom. heterocyclic ring].  
No biol. data is given.

RE.CNT 4



RE

- (1) Farbwerke Hoechst Aktiengesellschaft; DE 896809 C 1952
- (2) Galullo, V; WO 9827098 A 1998
- (3) Hanson, G; EXPERT OPINION ON THERAPEUTIC PATENTS 1997, V7(7), P729 CAPLUS
- (4) Pfizer Ltd; EP 0424021 A 1991



L3 ANSWER 3 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 131:336949 MARPAT  
 TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.  
 IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9937923	A1	19991129	AU 1999-37923	19990511
PRAI	US 1998-85053		19980511		
	US 1999-127626		19990401		
	US 1999-129099		19990413		
	WO 1999-US10291		19990511		
GI					



AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicycyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U =  
 R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.;  
 R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed

by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO<sub>2</sub>NCO in CH<sub>2</sub>Cl<sub>2</sub> followed by treatment of the product with NaBH<sub>4</sub> in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC<sub>50</sub> = 0.02-0.56 .mu.M.

RE.CNT 4

RE

- (1) Ciba Geigy AG; EP 0337943 A 1989
- (2) Ciba Geigy AG; EP 0337944 A 1989
- (3) Gallagher, T; WO 9733883 A 1997
- (4) Galullo, V; WO 9827098 A 1998

L3 ANSWER 4 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 129:81749 MARPAT  
 TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors  
 IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.  
 PA Vertex Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 131 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9827098 A1 19980625 WO 1997-US23392 19971217

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG


US 5945418 A 19990831 US 1997-822373 19970320  
 AU 9856105 A1 19980715 AU 1998-56105 19971217  
 EP 951467 A1 19991027 EP 1997-952517 19971217

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO


CN 1244867 A 20000216 CN 1997-181382 19971217  
 NO 9902960 A 19990817 NO 1999-2960 19990617

PRAI US 1996-34288 19961218  
 US 1997-822373 19970320  
 US 1997-862925 19970610  
 WO 1997-US23392 19971217

GI



I



II

AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxy carbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were

prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z =

09/336,266

pyridazine-3,6-diyl) which was hydrolyzed to the amide and the product cyclized to give title compd. II.

L3 ANSWER 5 OF 23 MARPAT COPYRIGHT 2000 ACS

AN 129:69033 MARPAT

TI Multicomponent system for altering, degrading, or bleaching lignin, lignin-containing materials, or similar substances, and method for its use

IN Freudenreich, Johannes; Stohrer, Juergen; Amann, Manfred; Mueller, Robert

PA Consortium fuer Elektrochemische Industrie G.m.b.H., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19651099	A1	19980610	DE 1996-19651099	19961209
	WO 9826127	A1	19980618	WO 1997-EP6802	19971205
	W: AU, BR, CA, CN, JP, KR, NO, PL, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9855603	A1	19980703	AU 1998-55603	19971205
	AU 719140	B2	20000504		
	EP 943032	A1	19990922	EP 1997-952038	19971205
	R: AT, DE, ES, SE, PT, FI				
	CN 1240008	A	19991229	CN 1997-180387	19971205
	JP 2000505844	T2	20000516	JP 1998-526185	19971205
PRAI	DE 1996-19651099		19961209		
	WO 1997-EP6802		19971205		

AB The title comps., esp. useful in cellulose pulp manuf., contain oxidants,

mediators (hydroxylated heterocyclic amines bearing NO or SH groups or their derivs.), and optionally, oxidn. catalysts. Adding 20 mL H<sub>2</sub>O

contg.

65.3 mg 8-hydroxy-5-nitrosoquinoline (acidified to pH 4.5) and 5 mL H<sub>2</sub>O contg. 15 units of laccase (from Trametes versicolor) to 5 g (dry basis) delignified softwood pulp, kneading for 2 min, and holding in O at 45.degree./1-10 bar for 1-4 h gave pulp with lignin degrdn. 11.6%.

L3 ANSWER 6 OF 23 MARPAT COPYRIGHT 2000 ACS

AN 128:13212 MARPAT

TI Bradykinin antagonist quinoline derivatives

IN Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki;

Inoue, Takayuki; Tanaka, Hirokazu

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki; Inoue, Takayuki; Tanaka, Hirokazu

SO PCT Int. Appl., 65 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741104	A1	19971106	WO 1997-JP1415	19970424
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9724054	A1	19971119	AU 1997-24054	19970424
	EP 900203	A1	19990310	EP 1997-919665	19970424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2000509066	T2	20000718	JP 1997-538734	19970424
	US 6083959	A	20000704	US 1998-147193	19981026
PRAI	AU 1996-9526	19960429			
	WO 1997-JP1415	19970424			
GI					




I

AB Title compds. I (R1 = lower alkyl, R2 = a heterocyclic group, R3 = H, lower alkyl, halo, R4 = lower alkyl, halo, R5 = alkylamino, amido, X = lower alkylene) were prepd. by std. derivatizations of 8-hydroxyquinolines. The IC50 (M) was  $3.3 \times 10^{-9}$  for inhibition of bradykinin binding for 8-[2,6-dichloro-3-[N-methyl-N-[4-(dimethylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methyl-4-(1-pyrazolyl)quinoline dihydrochloride.

L3 ANSWER 7 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 127:161697 MARPAT  
 TI 2-Amino heterocycles and their therapeutic uses as leukotriene biosynthesis inhibitors  
 IN Es-Sayed, Mazen; Yamamoto, Masaru; Frobél, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen  
 PA Bayer Aktiengesellschaft, Germany; Es-Sayed, Mazen; Yamamoto, Masaru; Frobél, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen  
 SO PCT Int. Appl., 275 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724328	A1	19970710	WO 1996-EP5643	19961216
	W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, IS, JP, KE, KP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9713728	A1	19970728	AU 1997-13728	19961216
PRAI	GB 1995-26560		19951227		
	WO 1996-EP5643		19961216		
GI					



AB 2-Amino heterocycles R<sub>1</sub>R<sub>2</sub>NCOR<sub>3</sub> [I; R<sub>1</sub> = H, Me, (un)substituted 6-membered arom. heterocycle contg. .ltoreq.2 N atoms and optionally benzo-fused; R<sub>2</sub> = (un)substituted adamantyl, cycloalkyl, pyridyl, Ph, CH<sub>2</sub>Ph, tetralin-5-yl, 2-norbornyl, 1-azabicyclo[2.2.2]oct-3-yl; or NR<sub>1</sub>R<sub>2</sub> forms .alpha.-carboline residue; R<sub>3</sub> = (un)substituted or cyclic amino groups linked via a bond, carbonyl, or alkylene group] are disclosed. I can be used for the prodn. of medicaments which inhibit leukotriene synthesis  
 (in particular LTB<sub>4</sub>), and are esp. useful for the treatment and control of respiratory diseases and inflammatory processes (no data). For instance, condensation of 2-chloropyridine with 4-MeOC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> at 150.degree. gave 2-(4-methoxyanilino)pyridine, which reacted with ClCO<sub>2</sub>CCl<sub>3</sub> and then HN(CH<sub>2</sub>Ph)<sub>2</sub> in dioxane at 60.degree. to give title compd. II plus a byproduct.

L3 ANSWER 8 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 126:157289 MARPAT  
 TI Benzamide derivatives and their use as vasopressin antagonists  
 IN Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi;  
 Sato,

Kentaro; Tanaka, Hirokazu  
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; Setoi, Hiroyuki; Ohkawa,  
 Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sato, Kentaro; Tanaka,  
 Hirokazu

SO PCT Int. Appl., 322 pp.  
 CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9641795	A1	19961227	WO 1996-JP1533	19960606
	W: AU, CA, CN, HU, IL, JP, KR, MX, NZ, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2223869	AA	19961227	CA 1996-2223869	19960606
	AU 9659110	A1	19970109	AU 1996-59110	19960606
	EP 832061	A1	19980401	EP 1996-916324	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	CN 1192729	A	19980909	CN 1996-196175	19960606
	JP 11508244	T2	19990721	JP 1996-502896	19960606
	ZA 9604895	A	19961212	ZA 1996-4895	19960607
	US 6054457	A	20000425	US 1997-973103	19971209
PRAI	GB 1995-11694		19950609		
	WO 1996-JP1533		19960606		
GI					





AB The invention relates to new benzamide derivs. having vasopressin antagonistic activity, and to pharmaceutically acceptable salts thereof, processes for their prepn., and pharmaceutical compns. The compds. are represented by formula I [R1 = (un)substituted aryl, cycloalkyl, heterocyclyl; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, halo, OH, (un)substituted acyloxy, alkyl, (cyclo)alkoxy, NO<sub>2</sub>, amino, acyl; R4 = OH, halo, NO<sub>2</sub>, (un)substituted amino, acyloxy, alkoxy, alkylthio, alk(en/yn)yl, etc; R5 = H, alkyl, alkoxy, halo; A = bond, O, NH; E = alkylene, alkenylene, CO, SO<sub>2</sub>, etc.; X = CH:CH, CH:N, S; Y = CH, N]. Approx. 470 synthetic examples of I and over 100 intermediates are described. For instance, amidation of 2-(PhCH<sub>2</sub>O)C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H with 4-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CONMeC<sub>6</sub>H<sub>4</sub>[O(CH<sub>2</sub>)<sub>5</sub>CO<sub>2</sub>Et]-2 (prepn. given), followed by sapon. of the ester, amidation with N-methylpiperazine, hydrogenolytic debenzoylation, etherification with N-(3-bromopropyl)phthalimide, hydrazinolysis of the imide, and acidification, gave title compd. II as the di-HCl salt (III). In assays for binding at human vasopressin V<sub>1</sub> receptors and cloned human V<sub>2</sub> receptors in vitro, III had IC<sub>50</sub> values of 14 and 1400 nM, resp.

L3 ANSWER 9 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 126:48348 MARPAT  
 TI Colorants, printing ink compositions containing them and their use  
 IN Bradbury, Roy; Butters, Alan; Moscrop, Clive; Slark, Andrew  
 PA Zeneca Limited, UK; Bradbury, Roy; Butters, Alan; Moscrop, Clive; Slark, Andrew  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634916	A2	19961107	WO 1996-GB994	19960426
	WO 9634916	A3	19970103		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				



SE	EP 823927	A2	19980218	EP 1996-911052	19960426
	R: CH, DE, FR, GB, IT, LI				
	JP 11504958	T2	19990511	JP 1996-533099	19960426
	US 6099625	A	20000808	US 1998-945649	19980108
PRAI	GB 1995-8810	19950501			
	GB 1995-8874	19950502			
	WO 1996-GB994	19960426			

AB Ink compns. contain (XmZ)wX(ZlXn)Q and their salts, wherein Q is a chromophore which absorbs electromagnetic radiation; X is an interactive functional group; Z and Zl each independently is a spacer group; w and x each independently is 0 or an integer equal to or greater than 1; and m and n each independently is an integer equal to or greater than 1, provided that w and x are not both equal to zero and when one of w or x

is 0 at least one of m and n is equal to or greater than 2. The compns. are suited for ink jet printing and electrophotog. In an example, N,N-bis(3-hydroxypropyl)aniline was obtained from PhNH<sub>2</sub> and 3-chloro-1-propanol and coupled with diazotized 2-(4-aminophenyl)ethanol to give an azo dye.

L3 ANSWER 10 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 125:275894 MARPAT  
 TI Preparation of heterocyclic compounds as ACAT inhibitors  
 IN Ishikawa, Kiyofumi; Hayama, Takashi; Kamei, Toshio; Nagata, Yasufumi  
 PA Banyu Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626925	A1	19960906	WO 1996-JP412	19960223
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	JP 1995-65263		19950301		
	JP 1995-152173		19950526		
GI					



AB The title compds. I [Ar represents Ph, naphthyl or pyridyl optionally having one to four substituents selected from the group consisting of lower alkyl, lower alkoxy and halogeno; R1 represents hydrogen or lower alkyl; R2 and R3 may be the same or different and each represents hydrogen, lower alkyl, lower alkoxy, lower alkylthio, mono(lower alkyl)amino or di(lower alkyl)amino, provided that the lower alkyl, lower alkoxy, lower alkylthio, mono(lower alkyl)amino or di(lower alkyl)amino may be substituted by pyrrolidino, etc. at arbitrary hydrogen atoms; n represents 0, 1 or 2; and X represents CH or N] are prepd. The title compd. II (prepn. given) at 0.3 .mu.M gave 100% inhibition of ACAT.

L3 ANSWER 11 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 125:204523 MARPAT  
 TI Drugs for improvement of lipid metabolism  
 IN Shiraishi, Mitsuru; Watanabe, Toshifumi  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 111 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08175994	A2	19960709	JP 1995-244938	19950922
PRAI	JP 1994-263512		19941027		
GI					




AB Drugs of formula I (ring A is substituted benzene; ring B is substituted pyridine; Q = OH, OQ1, or Q1, where Q1 = substituted fatty hydrocarbon group; n = 0 or 1) and their pharmaceutically acceptable salts are prepd. for treatment of disorders of lipid metab. Thus, a capsules can be formulated which contain (Z)-2-(5-bromo-4-cyano-2-hydroxybenzoyl)-3-hydroxypyridine N-oxide O-tert-butyloxime (II) 1 mg, lactose 80 mg, microcryst. cellulose 60 mg, and magnesium stearate 9 mg. Given at 1 mg/kg dosage to rats with hypertriglyceridemia, II exhibited hypotriglyceridemic activity.

L3 ANSWER 12 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 124:232488 MARPAT  
 TI Piperazine, piperidine, and tetrahydropyridine derivatives of  
 indol-3-ylalkyl as 5-HT1D.alpha. agonists  
 IN Castro Pineiro, Jose Luis; Chambers, Mark Stuart; Hobbs, Sarah Christine;  
 Matassa, Victor Giulio; Reeve, Austin John; Showell, Graham Andrew;  
 Street, Leslie Joseph  
 PA Merck Sharp and Dohme Ltd., UK  
 SO PCT Int. Appl., 121 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9532196	A1	19951130	WO 1995-GB1129	19950518
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2190501	AA	19951130	CA 1995-2190501	19950518
	AU 9525296	A1	19951218	AU 1995-25296	19950518
	AU 694226	B2	19980716		
	EP 759918	A1	19970305	EP 1995-919502	19950518
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10501212	T2	19980203	JP 1995-530123	19950518
	ZA 9508271	A	19960517	ZA 1995-8271	19951002
	US 5807857	A	19980915	US 1996-737769	19961115
PRAI	GB 1994-10080		19940519		
	GB 1994-11954		19940615		
	GB 1994-15805		19940804		
	GB 1994-25448		19941216		
	WO 1995-GB1129		19950518		
GI					



I




II


AB Title compds. I and their salts and prodrugs are disclosed [wherein Z = (un)substituted furan, thiophene; pyrrole, oxazole, thiazolè, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, or tetrazole; E = bond or C1-4 straight or branched alkylene; Q = C1-6 straight or branched alkylene, (un)substituted by OH; T = N or CH; U = N or CR<sub>2</sub>; V = O, S, or NR<sub>3</sub>; W-G = CH<sub>2</sub>N, CH<sub>2</sub>CH, or CH:C; R<sub>1</sub> = (un)substituted C3-6 alkenyl or alkynyl, (hetero)arylalkyl; R<sub>2</sub>, R<sub>3</sub> = H or C1-6 alkyl]. I show selective affinity for the 5-HT<sub>1D</sub>.alpha. receptor subtype, relative to the 5-HT<sub>1D</sub>.beta. subtype. I are useful for treatment and/or prevention of migraine and assocd. disorders, for which a subtype-selective agonist of 5-HT<sub>1D</sub>.alpha. receptors should elicit fewer side-effects, notably adverse cardiovascular events. Fifty-eight synthetic examples are given. For example, cyclocondensation of 4'-(1,2,4-triazol-4-yl)phenylhydrazine with 5-[4-(tert-butoxycarbonyl)piperazin-1-yl]pentanal di-Me acetal [prepns. given] in 4% H<sub>2</sub>SO<sub>4</sub> gave 44% of a corresponding (indolylpropyl)piperazine deriv., which was N-alkylated with 4-(acetamido)benzaldehyde and NaBH<sub>3</sub>CN (50%) to give title compd. II. In 3 bioassays, all tested I showed at least 10-fold selectivity for 5-HT<sub>1D</sub>.alpha. over 5-HT<sub>1D</sub>.beta. receptors (no data for specific compds.).

L3 ANSWER 13 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 124:175614 MARPAT  
 TI Process for the preparation of intermediates useful in the preparation of  
 pyranyl cyanoguanidine derivatives  
 IN Godfrey, Jollie D., Jr.; Mueller, Richard H.; Sedergran, Thomas C.;  
 Soundararajan, Nachimuthu  
 PA Squibb, E. R., and Sons, Inc., USA  
 SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 975,498, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5463059	A	19951031	US 1993-128436	19931001
	EP 600617	A1	19940608	EP 1993-308845	19931105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	FI 9304947	A	19940511	FI 1993-4947	19931109
	AU 9350543	A1	19940526	AU 1993-50543	19931109
	AU 660239	B2	19950615		
	HU 68501	A2	19950628	HU 1993-3185	19931109
	JP 06219985	A2	19940809	JP 1993-281067	19931110
	CN 1094712	A	19941109	CN 1993-114524	19931110
	US 5536833	A	19960716	US 1995-452238	19950526
PRAI	US 1992-975498		19921110		
	US 1993-128436		19931001		
GI					



I




II

AB The title compds. [I; A, B, D are all C atoms or one is N or NO and the others are C atoms; R1, R2 = H, alkyl, arylalkyl; R3 = H, (un)substituted alkyl, CN, NO2, etc; R4 = H, alkyl, OH, alkoxy, (un)substituted NH2] [e.g., 4-[(1,1-dimethyl-2-propynyl)oxy]benzonitrile] are prepd. by alkylating a substituted phenol (II) (e.g., 4-cyanophenol) with an alkyne HC.tplbond.CC(X)R1R2 (X = Cl, Br, etc.) (e.g., 3-chloro-3-methyl-1-butyne) in the presence of a catalytic amt. of a cuprous (e.g., CuCl) or cupric salt.

L3 ANSWER 14 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 123:285792 MARPAT  
 TI Preparation of pyridyl-naphthalene and pyridonyl-naphthalene derivatives as antiasthmatics  
 IN Iwasaki, Tameo; Kondo, Kazuhiko; Ikezawa, Ichiro; Yoshikawa, Hideo; Yamagata, Shinsuke  
 PA Tanabe Seiyaku Co, Japan  
 SO Jpn. Kokai Tokkyo Koho, 45 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07101861	A2	19950418	JP 1994-183128	19940804
PRAI	JP 1993-198308		19930810		
GI					




AB The title compds. I [R1, R2 = H, (un)substituted alkoxy, etc.; or R1R2 = alkylendioxy; R3 = (un)substituted N-contg. 6-membered heterocyclic ring;  
 OR4, OR5 = (protected) OH] are prepd. I [R1 = R2 = EtO; R4 = R5 = H; R3 = Q1] (II) (prepn. given) at 3 mg/Kg i. v. gave complete inhibition of histamine-induced bronchoconstriction in guinea pigs. II at 10 mg/Kg i. v. gave 63% inhibition of antigen-induced bronchoconstriction in guinea pigs. I [R1 = EtO; R2 = MeO; R3 = Q1; R4 = R5 = H] at 10 mg/Kg i. v. gave 80% inhibition of antigen-induced bronchoconstriction in guinea pigs.



L3 ANSWER 15 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 123:198800 MARPAT  
 TI Preparation of [(azacyclomethyl)heterocyclyl]alkanoates and analogs as  
 angiotensin II receptor antagonists  
 IN Carpino, Philip A.; Larson, Eric R.; Mylari, Banavara L.  
 PA USA  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9502596	A1	19950126	WO 1994-IB187	19940701
	W: AU, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9469794	A1	19950213	AU 1994-69794	19940701
	FI 9403359	A	19950116	FI 1994-3359	19940714
	BR 9500208	A	19970114	BR 1995-208	19950113
	US 5789415	A	19980804	US 1996-569133	19960111
PRAI	US 1993-92349		19930715		
	WO 1994-IB187		19940701		
GI					




II

AB RCH2ZCR1R2R3 [I; R = azacyclyl group; R1,R2 = H, OH, alkyl, Ph, etc.;  
 R1R2 = atoms to complete a (heterocyclic) ring; R3 = CHO, CO2H, CH2OH, tetrazolyl, etc.; Z = naphthylene, heterocyclylene, etc.] were prepd.  
 Thus, Et 2-thienylacetate was cyclocondensed with cis-ClCH2CH:CHCH2Cl and the product formylated to give, in 2 addnl. steps, Et  
 1-(5-chloromethyl-2-thienyl)cyclopent-3-enecarboxylate which was condensed with  
 2-ethyl-5,7-dimethylimidazo[4,5-b]pyridine to give, after sapon., title compd. II. I had IC50 of .ltoreq.10-5M against SARILE AII binding at rat liver prepn. in vitro.

L3 ANSWER 16 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 121:108774 MARPAT  
 TI Preparation of thiazole derivatives as insecticides and agrochemical and medical fungicides  
 IN Kumita, Izumi; Noda, Kaoru; Hashimoto, Sho; Matsuda, Michihiko; Iwasa, Takao  
 PA Nippon Soda Co., Ltd., Japan  
 SO PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9401423	A1	19940120	WO 1993-JP926	19930706
	W: CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 06073032	A2	19940315	JP 1993-191584	19930706
PRAI	JP 1992-201787		19920707		
GI					



L3 ANSWER 17 OF 23 MARPAT COPYRIGHT 2000 ACS

(ALL HITS ARE ITERATION INCOMPLETES)

AN 120:245602 MARPAT

TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors

IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9342521	A1	19931213	AU 1993-42521	19930519
	AU 668180	B2	19960426		
	EP 641204	A1	19950308	EP 1993-911358	19930519
	EP 641204	B1	20000816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07508038	T2	19950907	JP 1993-503831	19930519
	US 5536727	A	19960716	US 1994-338572	19941117
PRAI	US 1992-886031		19920520		
	WO 1993-US4746		19930519		

GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe;


R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepd. as inhibitors of steroid 5.alpha.-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to

give

17-diphenylmethoxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one.

L3 ANSWER 18 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 120:19165 MARPAT  
 TI Use of heterocyclic nitrogen addenda to reduce continued coupling of  
 magenta dye-forming couplers  
 IN Merkel, Paul Barrett; Singer, Stephen Paul  
 PA Eastman Kodak Co., USA  
 SO Eur. Pat. Appl., 23 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 545248	A1	19930609	EP 1992-120066	19921125
	EP 545248	B1	19950927		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	US 5441851	A	19950815	US 1991-797660	19911125
	JP 05241297	A2	19930921	JP 1992-313577	19921124
PRAI	US 1991-797660		19911125		
GI					



AB The title material comprises a 2-equiv. pyrazolone magenta coupler and a heterocyclic N-compd. selected from protic imidazoles I and pyridine compds. II [R1, R2 = H, alkyl, alkenyl, alkoxy, aryl, III (one of R3 and R4 is alkylene and the other one is H, alkyl, alkenyl) with the proviso that .ltoreq.1 of R1 and R2 is III.

L3 ANSWER 19 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 117:26560 MARPAT  
 TI Preparation of heterocyclo-fused imidazoles as angiotensin II antagonists  
 IN Ries, Uwe; Narr, Berthold; Bomhard, Andreas; Hael, Norbert; Van Meel, Jacques; Wienen, Wolfgang; Entzeroth, Michael  
 PA Thomae, Dr. Karl, G.m.b.H., Germany  
 SO Eur. Pat. Appl., 68 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 470543	A1	19920212	EP 1991-113121	19910805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4025358	A1	19920213	DE 1990-4025358	19900810
	DE 4031601	A1	19920423	DE 1990-4031601	19901005
	DE 4105827	A1	19920827	DE 1991-4105827	19910225
	CA 2048809	AA	19920211	CA 1991-2048809	19910808
	AU 9181717	A1	19920213	AU 1991-81717	19910809
	AU 650278	B2	19940616		
	HU 59140	A2	19920428	HU 1991-2665	19910809
	JP 06340665	A2	19941213	JP 1991-199654	19910809
PRAI	DE 1990-4025358		19900810		
	DE 1990-4031601		19901005		
	DE 1991-4105827		19910225		
GI					



AB Title compds. I [1 or 2 of A1, A2, A3, A4 = N and the remainder = CH; R1 = H, Br, Cl, F, HO, alkyl, alkoxy, (substituted) (acyl)amino, (substituted) pyrrolidino, -piperidino, -hexamethyleneimino, -phthalimido, -2-oxoisindolin-1-yl, -ureido; R2 = H, C1-3 alkyl; R3 = C1-6 alkyl; R4 = HO2C, NC, 1H-tetrazolyl, 1-trityltetrazolyl, C2-5 alkoxycarbonyl; R5 = H, Br, Cl, F, etc.], isomers, tautomers, enantiomers, and salts thereof, were  
 prepd. tert-Bu 4'-[(2-n-butyl-5-methyl-6-phthalimido-3H-imidazo[4,5-b]pyridin-3-yl)methyl]biphenyl-2-carboxylate in CH2Cl2 was treated with F3CCO2H to give I (A1 = A2 = A3 = HC, A4 = N, R1 = 6-phthalimido, R2 = 5-Me, R3 = Bu, R4 = HO2C, R5 = H) (II). In rats, II and several addnl. I at 10, 20 and 30 mg/kg i.v. antagonized angiotensin II-induced increase  
 in  
 arterial blood presssure with pA2 values of 5.1-8.5. I showed no toxic effects at the above dosage levels. Pharmaceutical formulations

09/336,266

comprising I are given.

L3 ANSWER 20 OF 23 MARPAT COPYRIGHT 2000 ACS  
(ALL HITS ARE ITERATION INCOMPLETES)

AN 116:13416 MARPAT

TI Pressure- and heat-sensitive recording materials with good sensitivity,  
storability and image stability

IN Sano, Masajiro; Takashima, Masanobu; Satomura, Masato

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent



LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03142277	A2	19910618	JP 1989-282319	19891030
AB	The title materials utilizes coloration by contact between electron-donating leuco dye Ar1R1CH:CR2:CH:CHR3CR4R5Ar2 (Ar1, Ar2 = amine residue-contg. aryl or heterocyclic group; R1-4 = H, monovalent group; R5 = aryl group-contg. alkoxy group; R1-4 may bond together forming 4- to 12-membered rings with or without contg. heteroatom) and electron-accepting compd.				

L3 ANSWER 21 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 115:71405 MARPAT  
 TI Preparation of Me 7-[6-(dimethylamino)-4-(4-fluorophenyl)-2-isopropylpyridinyl]-3,5-dihydroxyheptenoates and analogs as HMG CoA reductase inhibitors  
 IN Fey, Peter; Angerbauer, Rolf; Huebsch, Walter; Philipps, Thomas; Bischoff, Hilmar; Petzinna, Dieter; Schmidt, Delf  
 PA Bayer A.-G., Fed. Rep. Ger.  
 SO Ger. Offen., 37 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3929507	A1	19910307	DE 1989-3929507	19890906
	US 5145857	A	19920908	US 1990-568442	19900815
	EP 416383	A2	19910313	EP 1990-116202	19900824
	EP 416383	A3	19911106		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03093773	A2	19910418	JP 1990-230746	19900903
	DD 299295	A5	19920409	DD 1990-343797	19900903
	IL 95563	A1	19940624	IL 1990-95563	19900903
	CA 2024576	AA	19910307	CA 1990-2024576	19900904
	AU 9062170	A1	19910314	AU 1990-62170	19900904
	AU 637632	B2	19930603		
	ZA 9007054	A	19910731	ZA 1990-7054	19900905
	HU 56546	A2	19910930	HU 1990-5809	19900906
PRAI	DE 1989-3929507		19890906		
GI					







AB The title compds. [I; R = CHOHCH<sub>2</sub>CR<sub>4</sub>OHCH<sub>2</sub>CO<sub>2</sub>R<sub>7</sub>, hydroxylactone moiety Q; R<sub>1</sub> = (un)substituted C<sub>6</sub>-10 aryl; R<sub>2</sub> = CH<sub>2</sub>OR<sub>8</sub>, XR; R<sub>3</sub>, R<sub>4</sub> = H, C<sub>1</sub>-8 alkyl, Ph, AR<sub>9</sub>; NR<sub>3</sub>R<sub>4</sub> = 5- to 7-membered (un)satd. heterocyclyl group with 1 to 3 heteroatoms; R<sub>5</sub> = C<sub>1</sub>-10 alkyl, C<sub>3</sub>-8 cycloalkyl; R<sub>6</sub> = H, C<sub>1</sub>-10 alkyl; R<sub>7</sub>, R<sub>8</sub> = (un)substituted C<sub>1</sub>-10 alkyl; R<sub>9</sub> = amino, (un)substituted C<sub>1</sub>-8 alkyl, alkoxy, Ph; X = CH<sub>2</sub>CH<sub>2</sub>, CH:CH; A = CO, SO<sub>2</sub>] and their salts, HMG CoA reductase inhibitors useful as antihypercholesterolemics and for the treatment of hyperlipoproteinemia and atherosclerosis (no data), were prepd. The intermediate ketones were also claimed. A soln. of 6-dimethylamino-4-(4-fluorophenyl)-2-isopropylpyridine-3,5-dicarbaldehyde (multistep prepn. given) was coupled with di-Et [2-(cyclohexylamino)vinyl]phosphonate, the resulting 3,5-di(prop-2-en-1-yl) compd. condensed with MeCOCH<sub>2</sub>CO<sub>2</sub>Me, and the product reduced by Et<sub>3</sub>B/NaBH<sub>4</sub> to give title compd. II.

L3 ANSWER 22 OF 23 MARPAT COPYRIGHT 2000 ACS  
 AN 114:101740 MARPAT  
 TI Preparation of fungicidal anilinocyanopyridines  
 IN Schubert, Juergen; Wild, Jochen; Harreus, Albrecht; Kuekenhoechner, Thomas;  
 Sauter, Hubert; Ammermann, Eberhard; Lorenz, Gisela  
 PA BASF A.-G., Fed. Rep. Ger.  
 SO Ger. Offen., 28 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3905238	A1	19900823	DE 1989-3905238	19890221
	CA 2008588	AA	19900821	CA 1990-2008588	19900125
	US 5081133	A	19920114	US 1990-470309	19900125
	IL 93171	A1	19930818	IL 1990-93171	19900125
	EP 384311	A1	19900829	EP 1990-103017	19900216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
	AU 9049931	A1	19900830	AU 1990-49931	19900220
	AU 620211	B2	19920213		
	HU 53877	A2	19901228	HU 1990-865	19900220
	HU 203726	B	19910930		
	ZA 9001258	A	19911030	ZA 1990-1258	19900220
	JP 02255657	A2	19901016	JP 1990-38561	19900221
PRAI	DE 1989-3905238		19890221		

GI



AB Title compds. I [X = NO<sub>2</sub>, cyano, halo, alkylsulfonyl, (halo) C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, (substituted) PhO or PhS; m = 1-3 and X groups are same or different when m > 1; R<sub>1</sub> = H, halo, (halo)alkoxy, haloalkyl, (substituted) PhO or PhS; R<sub>2</sub>, R<sub>3</sub> = H, halo, NO<sub>2</sub>, cyano, (halo)alkyl, alkylsulfonyl, SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub> (R<sub>5</sub>, R<sub>6</sub> = H, C1-4 alkyl), haloalkoxy,

CO2R5, CONR5R6; R4 = H, CO2R7 (R7 = halo(alkyl), PhCH2, (substituted aryl), CONR5R6, CHO, COR7, SO2R7, C3-6 alkenyl or alkynyl], useful as fungicides, were prepd. For example, reaction of 2-amino-3,5-dicyano-6-ethoxy-4-isopropylpyridine with 3-chloro-2,6-dinitro-4-trifluoromethylchlorobenzene gave title compd. II in 58% yield. A foliar spray contg. II (0.05% by wt.) showed 95-100% control against *Plasmopara viticola* on grapes vs. 70% control by 2-(2,4-dinitro-6-trifluoromethylanilino)-5-trifluoromethylpyridine.

L3 ANSWER 23 OF 23 MARPAT COPYRIGHT 2000 ACS

AN 109:6320 MARPAT

TI Preparation of 2-[(pyridinioamino)alkyl]penemcarboxylates as antibacterial

agents

IN Schneider, Peter

PA Ciba-Geigy A.-G., Switz.

SO Eur. Pat. Appl., 23 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 256990	A1	19880224	EP 1987-810462	19870814
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 8703556	A	19880221	FI 1987-3556	19870817
	DK 8704321	A	19880221	DK 1987-4321	19870819
	NO 8703500	A	19880222	NO 1987-3500	19870819
	AU 8777217	A1	19880225	AU 1987-77217	19870819
	JP 63051387	A2	19880304	JP 1987-204285	19870819
	ZA 8706135	A	19880427	ZA 1987-6135	19870819
PRAI	CH 1986-3346		19860820		
GI					



AB The title compds. [I; R1 = CH2OH, MeCHOH; Z = 2- and 4-pyridinio group, Q or Q1; R2 = (un)substituted alkyl, alkenyl, Ph, pyridyl, etherified OH; R3, R4 = H, (un)substituted alkyl, NH2, (un)derivatized CO2H, etherified or esterified OH; m = 1-4] were prepd. (5R,6S)-2-Aminomethyl-6-[(1R)-1-hydroxyethyl]-2-penamcarboxylic acid and 4-chloro-2-hydroxymethyl-1-methylpyridinium iodide (prepn. given) were stirred 5 h in aq. soln. maintained at pH 7.5-7.9 to give I [R1 = (1R)-MeCHOH, Z = Q, R2 = Me, R3 =

=

2-(CH2OH), R4 = H] (II). Dry ampuls were prepd. each contg. 0.5 g II and 0.5 g mannitol. I are effective against, e.g., *Staphylococcus aureus* at <0.01 to .apprx.16 .mu.g/mL, *Pseudomonas aeruginosa* at 0.01 to .apprx.64 .mu.g/mL, and *Bacteroides fragilis* at 0.01 to .apprx.2 .mu.g/mL.

09/336,266

=>


Uploading 336266eg.str

L1 STRUCTURE UPLOADED

=> d l1


L1 HAS NO ANSWERS

L1 STR



cy2

(If) ang (If)



G1 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:25:54 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 1481 TO ITERATE

67.5% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 27313 TO 31927  
PROJECTED ANSWERS: 4 TO 264

L2 4 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 15:26:03 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 29616 TO ITERATE

100.0% PROCESSED 29616 ITERATIONS  
SEARCH TIME: 00.00.05

55 ANSWERS

09/336,266

L3            55 SEA SSS FUL L1

=> s 13

L4            2 L3

=> d 14 1-2 bib,ab,hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:736658 CAPLUS

DN 131:336949

TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.

IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9937923	A1	19991129	AU 1999-37923	19990511
PRAI	US 1998-85053		19980511		
	US 1999-127626		19990401		
	US 1999-129099		19990413		
	WO 1999-US10291		19990511		
OS	MARPAT 131:336949				
AB	Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicycyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.; R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Ti2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 .mu.M.				
IT	250122-79-3P	250122-80-6P	250122-81-7P	250122-91-9P	250122-92-0P
	250122-93-1P	250122-94-2P	250122-95-3P	250122-96-4P	250122-97-5P
	250122-98-6P	250122-99-7P	250123-00-3P	250123-01-4P	250123-02-5P
	250123-03-6P	250123-04-7P	250123-05-8P	250123-06-9P	250123-07-0P
	250123-08-1P	250123-09-2P	250123-10-5P	250123-11-6P	250123-12-7P
	250123-13-8P	250123-14-9P	250123-15-0P	250123-16-1P	250123-17-2P
	250123-18-3P	250123-19-4P	250123-20-7P		


250123-21-8P 250123-22-9P 250123-23-0P  
 250123-24-1P 250123-25-2P 250123-26-3P  
 250123-27-4P 250123-28-5P 250123-30-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)


RN 250122-79-3 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[5-(hydroxymethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-80-6 CAPLUS


CN Urea, N-[5-[(acetyloxy)methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-81-7 CAPLUS

CN Urea, N-[5-[[[aminocarbonyl]oxy]methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)






RN 250122-91-9 CAPLUS

CN Urea,


N-[5-[(aminocarbonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-  
N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-92-0 CAPLUS


CN Carbamic acid,

[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-  
methylphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 250122-93-1 CAPLUS


CN Urea, N'-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250122-94-2 CAPLUS


CN Urea,

N-[5-[(aminosulfonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 250122-95-3 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[5-[[[(dimethylamino)sulfonyl]amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 250122-96-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 250122-97-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 250122-98-6 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 250122-99-7 CAPLUS

CN Urea, N-[5-(aminomethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-00-3 CAPLUS


CN Urea, N-(2,6-difluorophenyl)-N-[5-[(dimethylamino)methyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-01-4 CAPLUS


CN Urea,

N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(1-hydroxy-1-methylethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 250123-02-5 CAPLUS

CN Urea, N-[5-(1-amino-1-methylethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 250123-03-6 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[5-[1-(dimethylamino)-1-methylethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-04-7 CAPLUS


CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-05-8 CAPLUS

CN Urea,


N-[5-(2-aminoethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-06-9 CAPLUS


CN Urea, N-(2,6-difluorophenyl)-N-[5-[2-(dimethylamino)ethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)






RN 250123-07-0 CAPLUS

3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 250123-08-1 CAPLUS

3-Pyridinepropanoic acid, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 250123-09-2 CAPLUS

CN 3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-10-5 CAPLUS

CN 3-Pyridineethanesulfonamide,  
6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-  
2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 250123-11-6 CAPLUS

CN 3-Pyridineethanesulfonamide,

6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-


2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-12-7 CAPLUS


CN Carbamic acid, [2-(1-piperazinyl)ethyl]-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)

09/336,266




RN 250123-13-8 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[5-(2-hydroxyethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-14-9 CAPLUS


CN Urea,  
N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-15-0 CAPLUS

CN Urea,


N-[4-(3-aminopropyl)-6-(3-chloro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-16-1 CAPLUS


CN Urea,

N-[4-(3-aminopropyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 250123-17-2 CAPLUS

CN Urea, N-[4-(3-aminopropyl)-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-18-3 CAPLUS


CN Urea,  
N-[6-(3-chloro-2-methylphenyl)-4-(1-piperazinylmethyl)-2-pyridinyl]-  
N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-19-4 CAPLUS


CN Urea,

N-[6-(3-chloro-2-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-20-7 CAPLUS


CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[4-(2-hydroxyethyl)-1-piperazinyl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-21-8 CAPLUS


CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[ (3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 250123-22-9 CAPLUS


CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-23-0 CAPLUS


CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)






RN 250123-24-1 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-25-2 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1,5-diazocin-1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 250123-26-3 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-5-methyl-1,5-diazocin-


09/336,266

1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 250123-27-4 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 250123-28-5 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-30-9 CAPLUS

CN Urea, N-[5-amino-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



IT 250122-90-8


RL: RCT (Reactant)

(prepn. of pyridinylarylsureas and related compds. as inhibitors of p38 kinase)

RN 250122-90-8 CAPLUS

CN Urea,

N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




IT 250122-86-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of pyridinylureas and related compds. as inhibitors of p38  
kinase)

RN 250122-86-2 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[5-formyl-6-(2-methylphenyl)-2-pyridinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 4

RE

- (1) Ciba Geigy AG; EP 0337943 A 1989
- (2) Ciba Geigy AG; EP 0337944 A 1989
- (3) Gallagher, T; WO 9733883 A 1997
- (4) Galullo, V; WO 9827098 A 1998

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS  
 AN 1998:424256 CAPLUS  
 DN 129:81749  
 TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors  
 IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.  
 PA Vertex Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 131 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617
PRAI	US 1996-34288		19961218		
	US 1997-822373		19970320		
	US 1997-862925		19970610		
	WO 1997-US23392		19971217		

OS MARPAT 129:81749

AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxy carbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1]

were

prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPH (Z = pyridazine-3,6-diyl) which was hydrolyzed to the amide and the product cyclized to give title compd. II.

IT 209411-90-5P 209411-91-6P 209411-92-7P

209411-93-8P 209411-94-9P 209411-95-0P

209411-96-1P 209411-97-2P 209411-98-3P


209411-99-4P 209412-00-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)


RN 209411-90-5 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-(6-phenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 209411-91-6 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)



RN 209411-92-7 CAPLUS


CN Urea, N-(2,6-dimethylphenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)



RN 209411-93-8 CAPLUS


09/336,266

CN Urea, N-[6-(4-chlorophenyl)-2-pyridinyl]-N-(2,6-dichlorophenyl)- (9CI)  
(CA INDEX NAME)




RN 209411-94-9 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)




RN 209411-95-0 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)




RN 209411-96-1 CAPLUS

CN Urea, N-(2,6-dimethylphenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)




RN 209411-97-2 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-methylphenyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)






RN 209411-98-3 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-  
(9CI) (CA INDEX NAME)


RN 209411-99-4 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-  
(9CI) (CA INDEX NAME)

RN 209412-00-0 CAPLUS

CN Urea, N-(6-chloro-1,3-benzodioxol-5-yl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-  
(9CI) (CA INDEX NAME)

09/336,266



09/336,266

=> d his

(FILE 'HOME' ENTERED AT 15:25:19 ON 31 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:23 ON 31 AUG 2000

L1 STRUCTURE UPLOADED

L2 4 S L1 SSS SAM

L3 55 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:26:17 ON 31 AUG 2000

L4 2 S L3

FILE 'CAOLD' ENTERED AT 15:27:23 ON 31 AUG 2000

=> s 13

L5 0 L3

09/336,266

=>


Uploading 336266fh.str

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR



Cy<sup>2</sup>



G1 [01], [02]

(Ie) & (Ig)

, Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:29:38 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 11866 TO ITERATE

8.4% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 230814 TO 243826  
PROJECTED ANSWERS: 31 TO 443

L2 1 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 15:29:50 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 239798 TO ITERATE

100.0% PROCESSED 239798 ITERATIONS  
SEARCH TIME: 00.00.17

95 ANSWERS

09/336,266

L3 95 SEA SSS FUL L1

=> s 13

L4 2 L3

=> d 14 1-2 bib,ab;hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:736658 CAPLUS

DN 131:336949

TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.

IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 99 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9937923	A1	19991129	AU 1999-37923	19990511
PRAI	US 1998-85053		19980511		
	US 1999-127626		19990401		
	US 1999-129099		19990413		
	WO 1999-US10291		19990511		
OS	MARPAT 131:336949				
AB	Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicycyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.;				
	R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Ti2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 .mu.M.				
IT	<b>250122-82-8P</b>				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)				
RN	250122-82-8 CAPLUS				
CN	2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-.alpha.-(2,6-dichlorophenyl)-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)				




IT 250123-29-6

RL: RCT (Reactant)

(prepn. of pyridinylarylsureas and related compds. as inhibitors of p38 kinase)

RN 250123-29-6 CAPLUS

CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-.alpha.-(2,6-dichlorophenyl)-4-[[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4

RE

- (1) Ciba Geigy AG; EP 0337943 A 1989
- (2) Ciba Geigy AG; EP 0337944 A 1989
- (3) Gallagher, T; WO 9733883 A 1997
- (4) Galullo, V; WO 9827098 A 1998

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS  
 AN 1998:424256 CAPLUS  
 DN 129:81749  
 TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors  
 IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.  
 PA Vertex Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 131 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617
PRAI	US 1996-34288		19961218		
	US 1997-822373		19970320		
	US 1997-862925		19970610		
	WO 1997-US23392		19971217		
OS	MARPAT 129:81749				
AB	Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxy carbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1]				
were	prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolyzed to the amide and the product cyclized to give title compd. II.				
IT	209410-92-4P	209410-98-0P	209410-99-1P		
	209411-00-7P	209411-01-8P	209411-02-9P		
	209411-03-0P	209411-04-1P	209411-05-2P		
	209411-06-3P	209411-07-4P	209411-08-5P		
	209411-09-6P	209411-10-9P	209411-11-0P		
	209411-12-1P	209411-13-2P	209411-14-3P		
	209411-15-4P	209411-16-5P	209411-17-6P		
	209411-18-7P	209411-19-8P	209411-20-1P		
	209411-21-2P	209411-22-3P	209411-23-4P		
	209411-24-5P	209411-25-6P	209411-26-7P		




209411-27-8P 209411-28-9P 209411-29-0P  
 209411-30-3P 209411-31-4P 209411-32-5P  
 209411-33-6P 209411-34-7P 209411-35-8P  
 209411-36-9P 209411-37-0P 209411-38-1P  
 209411-39-2P 209411-40-5P 209411-41-6P  
 209411-42-7P 209411-43-8P 209411-44-9P  
 209411-45-0P 209411-46-1P 209411-47-2P  
 209411-48-3P 209411-49-4P 209411-50-7P  
 209411-51-8P 209411-52-9P 209411-53-0P  
 209411-54-1P 209411-55-2P 209411-56-3P  
 209411-57-4P 209411-58-5P 209411-59-6P  
 209411-60-9P 209411-61-0P 209411-62-1P  
 209411-63-2P 209411-64-3P 209411-65-4P  
 209411-66-5P 209411-67-6P 209411-68-7P  
 209411-69-8P 209411-70-1P 209411-71-2P  
 209411-72-3P 209411-74-5P 209411-75-6P  
 209411-76-7P 209411-77-8P 209411-78-9P  
 209411-79-0P 209411-80-3P 209411-81-4P  
 209411-82-5P 209411-83-6P 209411-84-7P  
 209411-85-8P 209411-86-9P 209411-87-0P  
 209411-88-1P 209411-89-2P 209412-01-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)


RN 209410-92-4 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI)  
 (CA INDEX NAME)




RN 209410-98-0 CAPLUS


CN 2-Pyridineacetamide,  
 .alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-  
 (9CI) (CA INDEX NAME)



RN 209410-99-1 CAPLUS  
 CN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-00-7 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-01-8 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)


09/336,266




RN 209411-02-9 CAPLUS  
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-03-0 CAPLUS  
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-04-1 CAPLUS


CN 2-Pyridineacetamide, 6-(4-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-  
(9CI) (CA INDEX NAME)

RN 209411-05-2 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-methylphenyl)-  
(9CI) (CA INDEX NAME)


RN 209411-06-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-07-4 CAPLUS

CN 2-Pyridineacetamide, 6-(3-chloro-4-fluorophenyl)-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-08-5 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-09-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-phenyl- (9CI)  
(CA INDEX NAME)




RN 209411-10-9 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-  
[(hydroxyimino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 209411-11-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-nitrophenyl)-  
(9CI)  
(CA INDEX NAME)




RN 209411-12-1 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-13-2 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-14-3 CAPLUS

CN 2-Pyridineacetamide, 6-(3-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-15-4 CAPLUS


CN Benzoic acid, 4-[6-[2-amino-1-(2,6-dichlorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)






RN 209411-16-5 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-formylphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-17-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-thienyl)- (9CI)  
(CA INDEX NAME)




RN 209411-18-7 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-thienyl)- (9CI)  
(CA INDEX NAME)




RN 209411-19-8 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-nitrophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-20-1 CAPLUS

CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-21-2 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-formylphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-22-3 CAPLUS  
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-23-4 CAPLUS  
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-24-5 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-methoxyphenyl)-  
 (9CI) (CA INDEX NAME)



RN 209411-25-6 CAPLUS  
 CN 2-Pyridineacetamide, 6-(2,4-dichlorophenyl)-.alpha.-(2,6-dichlorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 209411-26-7 CAPLUS  
 CN 2-Pyridineacetamide, 6-(5-chloro-2-thienyl)-.alpha.-(2,6-dichlorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 209411-27-8 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-formylphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-28-9 CAPLUS


CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-29-0 CAPLUS  
 CN 2-Pyridineacetamide,  
 .alpha.-(2-chloro-6-fluorophenyl)-6-(4-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 209411-30-3 CAPLUS  
 CN 2-Pyridineacetamide,  
 .alpha.-(2-chloro-6-fluorophenyl)-6-(3-methylphenyl)-  
 (9CI) (CA INDEX NAME)




RN 209411-31-4 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-chloro-4-  
 fluorophenyl)- (9CI) (CA INDEX NAME)

09/336,266




RN 209411-32-5 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-33-6 CAPLUS

CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(2-methylphenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-34-7 CAPLUS


CN Benzoic acid, 4-[6-[2-amino-1-(2-chloro-6-fluorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-35-8 CAPLUS


CN 2-Pyridineacetamide,  
 .alpha.-(2-chloro-6-fluorophenyl)-6-(4-formylphenyl)-  
 (9CI) (CA INDEX NAME)






RN 209411-36-9 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2-thienyl)-  
(9CI) (CA INDEX NAME)




RN 209411-37-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-thienyl)-  
(9CI) (CA INDEX NAME)




RN 209411-38-1 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-39-2 CAPLUS  
 CN 2-Pyridineacetamide,  
 .alpha.-(2-chloro-6-fluorophenyl)-6-(3-chlorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 209411-40-5 CAPLUS  
 CN 2-Pyridineacetamide,  
 .alpha.-(2-chloro-6-fluorophenyl)-6-(3-formylphenyl)-  
 (9CI) (CA INDEX NAME)



RN 209411-41-6 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-42-7 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(5-chloro-2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-43-8 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2-formylphenyl)-


09/336,266

(9CI) (CA INDEX NAME)




RN 209411-44-9 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,5-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 209411-45-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-46-1 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[[2-hydroxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-47-2 CAPLUS


CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(3-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-48-3 CAPLUS

CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)


09/336,266



RN 209411-49-4 CAPLUS  
CN 2-Pyridineacetamide,  
.alpha.-(2-chloro-6-fluorophenyl)-6-(2-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-50-7 CAPLUS  
CN 2-Pyridineacetamide, 6-(2-benzofuranyl)-.alpha.-(2,6-dichlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-51-8 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-methoxyphenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-52-9 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-53-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-naphthalenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-54-1 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(4-amino-2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 209411-55-2 CAPLUS

CN 2-Pyridineacetamide, 6-benzo[b]thien-2-yl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)







RN 209411-56-3 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-formyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 209411-57-4 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[(phenylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 209411-58-5 CAPLUS  
 CN 2-Pyridineacetamide, 6-[2-[[2-(2-aminoethyl)amino]methyl]phenyl]-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-59-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[[2,3-dihydroxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 209411-60-9 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 209411-61-0 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-difluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-62-1 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 209411-63-2 CAPLUS  
 CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 209411-64-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 209411-65-4 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-66-5 CAPLUS

CN 2-Pyridineacetamide, 6-(2,3-dichlorophenyl)-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-67-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 209411-68-7 CAPLUS

CN 2-Pyridineacetamide, 6-(2-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-69-8 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,3-dimethylphenyl)-  
(9CI) (CA INDEX NAME)



RN 209411-70-1 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-ethylphenyl)-  
(9CI)

(CA INDEX NAME)




RN 209411-71-2 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(2-  
hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-72-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-74-5 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-75-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 209411-76-7 CAPLUS

CN 2-Pyridineacetamide, 6-[3,5-bis(trifluoromethyl)phenyl]-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-77-8 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-78-9 CAPLUS


CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 209411-79-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dimethylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 209411-80-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-81-4 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-82-5 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(methoxymethoxy)methylphenyl]- (9CI) (CA INDEX NAME)




RN 209411-83-6 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(methoxymethoxy)methylphenyl]- (9CI) (CA INDEX NAME)




RN 209411-84-7 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 209411-85-8 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 209411-86-9 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(6-chloro-1,3-benzodioxol-5-yl)-6-phenyl-  
(9CI) (CA INDEX NAME)




RN 209411-87-0 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 209411-88-1 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 209411-89-2 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



09/336,266

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	136.71	136.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-12.19	-12.19

STN INTERNATIONAL LOGOFF AT 13:40:00 ON 31 AUG 2000

=&gt;


Uploading 336266.str

L4 STRUCTURE UPLOADED

=&gt; d 14

L4 HAS NO ANSWERS

L4 STR

Cy<sup>2</sup> $A - \frac{1}{[A]_{0-2}} Cy$ 

G1 N, CH

G2 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=&gt; s 14 sss sam

SAMPLE SEARCH INITIATED 11:33:40 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 683 TO ITERATE

100.0% PROCESSED 683 ITERATIONS  
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 12093 TO 15227  
 PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=&gt; s 14 sss ful

FULL SEARCH INITIATED 11:33:57 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 12951 TO ITERATE

100.0% PROCESSED 12951 ITERATIONS

3 ANSWERS

09/336,266

SEARCH TIME: 00.00.02


L6                    3 SEA SSS FUL L4

=> d scan 16



09/336,266


L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI)  
MF C20 H14 Cl2 N2 O2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

09/336,266


L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI)  
MF C19 H14 Cl2 N2 O S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

09/336,266

L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 2-Pyridineacetamide,  
.alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-  
(9CI)  
MF C20 H16 Cl2 N2 O2



ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.90	127.95

FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 31 Aug 2000 VOL 133 ISS 9  
 FILE LAST UPDATED: 30 Aug 2000 (20000830/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

=> d his

(FILE 'HOME' ENTERED AT 11:24:05 ON 31 AUG 2000)

FILE 'REGISTRY' ENTERED AT 11:24:10 ON 31 AUG 2000

L1 STRUCTURE UPLOADED  
 L2 STRUCTURE UPLOADED  
 L3 20 S L2 SSS SAM

FILE 'STNGUIDE' ENTERED AT 11:25:46 ON 31 AUG 2000

FILE 'REGISTRY' ENTERED AT 11:33:02 ON 31 AUG 2000

L4 STRUCTURE UPLOADED  
 L5 0 S L4 SSS SAM  
 L6 3 S L4 SSS FUL

FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000

=> s 16

L7 1 L6

=> d 17 bib,ab,hitstr

09/336,266

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS

AN 1998:424256 CAPLUS

DN 129:81749

TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors

IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al..

PA Vertex Pharmaceuticals Inc., USA

SO PCT Int. Appl., 131 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617
PRAI	US 1996-34288		19961218		
	US 1997-822373		19970320		
	US 1997-862925		19970610		
	WO 1997-US23392		19971217		
OS	MARPAT 129:81749				
AB	Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1]				
	were				
	prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPH (Z = pyridazine-3,6-diyl) which was hydrolyzed to the amide and the product cyclized to give title compd. II.				
IT	209410-92-4P 209410-98-0P 209410-99-1P				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)				
RN	209410-92-4 CAPLUS				
CN	2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI)				
	(CA INDEX NAME)				



RN 209410-98-0 CAPLUS  
 CN 2-Pyridineacetamide,  
 .alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-  
 (9CI) (CA INDEX NAME)



RN 209410-99-1 CAPLUS  
 CN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA  
 INDEX NAME)



=&gt; file caold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	4.27	132.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

FILE 'CAOLD' ENTERED AT 11:35:11 ON 31 AUG 2000  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=&gt; d his

(FILE 'HOME' ENTERED AT 11:24:05 ON 31 AUG 2000)

FILE 'REGISTRY' ENTERED AT 11:24:10 ON 31 AUG 2000  
 L1 STRUCTURE UPLOADED  
 L2 STRUCTURE UPLOADED  
 L3 20 S L2 SSS SAM

FILE 'STNGUIDE' ENTERED AT 11:25:46 ON 31 AUG 2000

FILE 'REGISTRY' ENTERED AT 11:33:02 ON 31 AUG 2000  
 L4 STRUCTURE UPLOADED  
 L5 0 S L4 SSS SAM  
 L6 3 S L4 SSS FUL

FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000  
 L7 1 S L6

FILE 'CAOLD' ENTERED AT 11:35:11 ON 31 AUG 2000

=&gt; s 16

L8 0 L6